AMPH Stock — Amphastar Pharmaceuticals Inc.: Cash, EV, Pipeline

Share price

$24.53

Market cap

$1,042.0M

Cash

$290.1M

Enterprise value

$1,371.6M

Balance sheet

Cash	$290.1M
Debt	$619.7M
Net cash	-$329.6M
Enterprise value	$1,371.6M
Basic shares	42.5M shares
Fully diluted shares	57.6M shares
Fully diluted market cap	$1,412.0M
Cash per share	$6.83

Cash figures as of 2026-06-30. Database snapshot: 2026-09-22.

Price history

Loading AMPH daily closes…

Loading price history…

Pipeline assets

AMP-019

Stage not disclosed · Active Modality: intranasal epinephrine nasal spray

Indications

Emergency treatment of allergic reactions including anaphylaxis (Stage not disclosed)

Status note Prescription product candidate; filing does not state current development stage.

AMP-105

Stage not disclosed · Active Modality: peptide

Partnerships Hanxin / Anji: peptide proprietary product candidates licensed (economics not disclosed)

Indications

Multiple poorly treated cancers (Stage not disclosed)

Status note Described as a first-in-class peptide targeting a novel mechanism to modulate cell growth and metastasis.

AMP-107

Stage not disclosed · Active Modality: topical eye drop peptide

Target VEGFR (vascular endothelial growth factor receptor)

Partnerships Hanxin / Anji: peptide proprietary product candidates licensed (economics not disclosed)

Indications

Wet age-related macular degeneration (wet AMD) (Stage not disclosed)

Status note Described as the first non-injectable anti-VEGFR peptide, an alternative to routine eye injections.

AMP-109

Stage not disclosed · Active Modality: peptide-docetaxel conjugate

Partnerships Hanxin / Anji: peptide proprietary product candidates licensed (economics not disclosed)

Indications

Cancer (taxane-eligible) (Stage not disclosed)

Status note Designed to improve selectivity/bioavailability of docetaxel and reduce docetaxel-induced toxicity.

AMP-110

Stage not disclosed · Active Modality: synthetic human corticotropin (ACTH) analog peptide

Partnerships Hanxin / Anji: peptide proprietary product candidates licensed (economics not disclosed)

Status note Will target multiple indications per filing.

AMP-004

Stage not disclosed · Active Modality: biosimilar (interchangeable)

Aliases Insulin Aspart

Status note Interchangeable insulin product candidate; filing does not state whether this is the insulin candidate currently on file with the FDA.

AMP-005

Stage not disclosed · Active Modality: biosimilar (interchangeable)

Aliases Recombinant Human Insulin

Status note Interchangeable insulin product candidate.

AMP-028

Stage not disclosed · Active Modality: biosimilar

Status note Biosimilar outside the insulin portfolio; product identity not disclosed. API manufactured at the Eragny-sur-Epte, France facility.

BAQSIMI

Approved · Active Modality: nasal powder

Aliases glucagon nasal powder

Indications

Severe hypoglycemia (Approved)

Status note Approved branded product acquired from Eli Lilly in June 2023; transition services completed January 1, 2025.

Per-asset detail extracted from the 10-Q filed 2026-08-06. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.

No lead program on file for this company.

No active ClinicalTrials.gov trials matched to this company as sponsor or collaborator.

No specialist-fund holders in 13F data for this company.

AMPH — Amphastar Pharmaceuticals Inc.

Balance sheet

Price history

Pipeline assets